REDX.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 19:04):

Stats
Šios dienos apimtis	670 146
Vidutinė apimtis	892 747
Rinkos kapitalizacija	35.01M
EPS	£0 ( 2023-12-14 )
Kita pelno data	( £0 ) 2024-05-06
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.900
ATR14	£0.536 (5.96%)

Tūris Koreliacija

Ilgas: -0.14 (neutral)

Trumpas: 0.57 (weak)

Signal:(54.41) Neutral

Redx Pharma PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Redx Pharma PLC Koreliacija - Valiuta/Žaliavos

0.61
( weak )

0.31
( neutral )

0.38
( neutral )

0.49
( neutral )

-0.22
( neutral )

-0.18
( neutral )

Redx Pharma PLC Finansinės ataskaitos

Annual	2023
Pajamos:	£4.20M
Bruto pelnas:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2023
Pajamos:	£4.20M
Bruto pelnas:	£3.24M (77.15 %)
EPS:	£-0.0990

FY	2022
Pajamos:	£18.69M
Bruto pelnas:	£18.69M (100.00 %)
EPS:	£-0.0612

FY	2021
Pajamos:	£10.04M
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.127

Financial Reports:

No articles found.

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.